Premier Path Wealth Partners LLC Cuts Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Premier Path Wealth Partners LLC lowered its stake in Edwards Lifesciences Co. (NYSE:EW) by 10.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 3,807 shares of the medical research company’s stock after selling 467 shares during the quarter. Premier Path Wealth Partners LLC’s holdings in Edwards Lifesciences were worth $282,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. FSA Wealth Management LLC acquired a new position in shares of Edwards Lifesciences during the third quarter valued at approximately $30,000. Prospera Private Wealth LLC acquired a new position in Edwards Lifesciences in the 3rd quarter valued at $32,000. Avior Wealth Management LLC raised its stake in Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares during the last quarter. Peoples Bank KS purchased a new position in Edwards Lifesciences in the 3rd quarter valued at $40,000. Finally, JFS Wealth Advisors LLC grew its holdings in shares of Edwards Lifesciences by 31.1% during the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after buying an additional 166 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analysts Set New Price Targets

EW has been the topic of several research reports. Citigroup raised their price target on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Canaccord Genuity Group boosted their target price on Edwards Lifesciences from $63.00 to $68.00 and gave the stock a “hold” rating in a report on Thursday, December 5th. Robert W. Baird cut their price target on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Stifel Nicolaus boosted their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the stock a “hold” rating in a research note on Thursday, December 5th. Finally, Piper Sandler cut their target price on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $78.48.

Insiders Place Their Bets

In other news, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the sale, the insider now directly owns 198,526 shares in the company, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Daniel J. Lippis sold 500 shares of the business’s stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the transaction, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. The trade was a 2.11 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 33,000 shares of company stock worth $2,195,180 over the last 90 days. Corporate insiders own 1.27% of the company’s stock.

Edwards Lifesciences Price Performance

EW stock opened at $69.77 on Monday. The business’s fifty day moving average price is $72.06 and its 200 day moving average price is $71.32. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $41.15 billion, a PE ratio of 10.07, a P/E/G ratio of 3.77 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.67. The business had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business’s quarterly revenue was up 8.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.59 earnings per share. On average, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.56 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.